Abstract: Plant T-DNA expression vectors encoding a post-translational modification (PTM) enzyme wherein the nucleic acid encoding the PTM enzyme has neither a promoter nor a 5? untranslated region (UTR) are provided. Also provided are methods of optimizing expression and glycosylation of recombinant protein produced in plants by utilizing the plant T-DNA expression vectors.

Abstract: Plant T-DNA expression vectors encoding a post-translational modification (PTM) enzyme wherein the nucleic acid encoding the PTM enzyme has neither a promoter nor a 5? untranslated region (UTR) are provided. Also provided are methods of optimizing expression and glycosylation of recombinant protein produced in plants by utilizing the plant T-DNA expression vectors.

Abstract: A plant or plant cell with reduced endogenous AGO1 and AGO4 expression compared to a wild-type plant or plant cell is provided. In one embodiment, the plant or plant cell further comprises a nucleic acid sequence encoding a recombinant protein and the plant or plant cell has increased expression of the recombinant protein compared to a wild-type plant or plant cell comprising the nucleic acid sequence. Methods of reducing aglycosylation of recombinant protein produced in plants are also provided.

Abstract: A genetically modified plant or plant cell with reduced ?1,3-fucosyltransferase and ?1,2-xylosyltransferase activity compared to a wild type plant or plant cell, wherein less than 10% of the total glycan on a protein produced by the plant or plant cell is ?1,3-fucosylated glycan and less than 3% of the total glycan on the protein is ?1,2-xylosylated glycan is provided. In one embodiment, the plant or plant cell comprises three T-DNA insertions expressing five copies of RNAi targeting ?1,3-fucosyltranserase and three copies of RNAi targeting ?1,2xylosyltransferase.

Abstract: Plant T-DNA expression vectors with engineered 5? sequences for driving transcription of genes encoding post-translational modification enzymes are provided. Also methods of optimizing expression and glycosylation of recombinant protein produced in plants by utilizing plant T-DNA expression vectors with engineered 5? sequences for driving transcription of genes encoding post-translational modification enzymes.

Abstract: A plant or plant cell with reduced endogenous AGO1 and AGO4 expression compared to a wild-type plant or plant cell is provided. In one embodiment, the plant or plant cell further comprises a nucleic acid sequence encoding a recombinant protein and the plant or plant cell has increased expression of the recombinant protein compared to a wild-type plant or plant cell comprising the nucleic acid sequence. Methods of reducing aglycosylation of recombinant protein produced in plants are also provided.

Abstract: A genetically modified plant or plant cell with reduced ?1,3-fucosyltransferase and ?1,2-xylosyltransferase activity compared to a wild type plant or plant cell, wherein less than 10% of the total glycan on a protein produced by the plant or plant cell is ?1,3-fucosylated glycan and less than 3% of the total glycan on the protein is ?1,2-xylosylated glycan is provided. In one embodiment, the plant or plant cell comprises three T-DNA insertions expressing five copies of RNAi targeting ?1,3-fucosyltranserase and three copies of RNAi targeting ?1,2xylosyltransferase.

Abstract: Expression vectors and methods of their use for enhancing the production of recombinant proteins in plants or plant cells are described. Production can be further enhanced upon co-expression of the P19 suppressor of gene-silencing from tomato bushy stunt virus. Preferably, the recombinant proteins are therapeutic enzymes and/or antibodies and methods are carried out in Nicotiana benthamiana—optionally an RNAi-based glycomodified strain—or in the Nicotiana tabacum cultivar Little Crittenden.

Abstract: The present disclosure relates to methods and uses of improving the therapeutic efficacy and utility of antibody fragments by employing anti-epitope-tagging technologies.

Abstract: A method of making an antibody in plants that binds to a HER receptor is described. The antibody preferably contains sequences from trastuzumab that have been optimized for expression in plants.

Abstract: A method of constructing a VHH library from an immunized camelid, using whole venom or an extract thereof. There is also provided VHH antibody fragments isolated from a library produced in hyperimmunized llama. These VHH antibody fragments were sequenced, and specifically bind ?-cobratoxin.

Abstract: Expression vectors and methods of their use for enhancing the production of recombinant proteins in plants or plant cells are described. Production can be further enhanced upon co-expression of the P19 suppressor of gene-silencing from tomato bushy stunt virus. Preferably, the recombinant proteins are therapeutic enzymes and/or antibodies and methods are carried out in Nicotiana benthamiana—optionally an RNAi-based glycomodified strain—or in the Nicotiana tabacum cultivar Little Crittenden.

Abstract: The present disclosure relates to methods and uses of improving the therapeutic efficacy and utility of antibody fragments by employing anti-epitope-tagging technologies.

Abstract: A method of constructing a VHH library from an immunized camelid, using whole venom or an extract thereof. There is also provided VHH antibody fragments isolated from a library produced in hyperimmunized llama. These VHH antibody fragments were sequenced, and specifically bind to ?-cobratoxin.

Abstract: A method of constructing a VHH library from an immunized camelid, using whole venom or an extract thereof There is also provided VHH antibody fragments isolated from a library produced in hyperimmunized llama These VHH antibody fragments were sequenced, and specifically bind ?-cobratoxin.

Abstract: A method of making an antibody in plants that binds to a HER receptor is described. The antibody preferably contains sequences from trastuzumab that have been optimized for expression in plants.

Abstract: The present disclosure relates to methods and uses of improving the therapeutic efficacy and utility of antibody fragments by employing anti-epitope-tagging technologies.

Abstract: A method of constructing a VHH library from an immunized camelid, using whole venom or an extract thereof There is also provided VHH antibody fragments isolated from a library produced in hyperimmunized llama These VHH antibody fragments were sequenced, and specifically bind ?-cobratoxin.